

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	ONCOSIL MEDICAL LTD
ABN:	89 113 824 141

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	NIGEL LANGE
Date of last notice	14 June 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	25 October 2022
No. of securities held prior to change	(1) 6,218,303 Fully Paid Ordinary Shares (including 5,718,303 Performance Dependent Loan Shares) (2) 2,841,633 Performance Rights in accordance with shareholder approval obtained at the Annual General Meeting on 19 October 2021.
Class	Performance Rights
Number acquired	2,469,795 Performance Rights
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil for the issue of 2,469,795 performance rights. The Performance Rights were issued under the OncoSil Omnibus Incentive Plan in accordance with shareholder approval at the AGM on 25 October 2022.
No. of securities held after change	(1) 6,218,303 Fully Paid Ordinary Shares (including 5,718,303 Performance Dependent Loan Shares) (2) 5,311,428 Performance Rights
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	2,469,795 Performance Rights were issued with shareholder approval at the AGM on 25 October 2022.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---------------------------------------------------------------------------------------------------------------------------------------------------------------	----

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.